ATLANTA -- Plasma-derived human apolipoprotein A1 (CSL112) infusions failed to improve outcomes for acute myocardial infarction (MI) patients with multivessel coronary artery disease and other ...

A team of Ohio University researchers have made a groundbreaking development in the fight against obesity. In a study ...

Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next generation biopharma company dedicated to ...

People in the UAE with a specific genetic variant are at greater risk from air pollution than those without it, a study has ...

Wim A. van der Steeg, M.D.; Christopher P. Cannon, M.D., F.A.C.C. As extensively discussed in literature, this unexpected outcome is hypothesized to relate to the ...

A new study published in the Journal of American Medical Association showed that the innovative small interfering RNA (siRNA) medication olpasiran (Amgen) can effectively reduce lipoprotein(a) ...

Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...

In this randomized controlled trial, among patients with persistent chylomicronemia, it was found that plozasiran more ...

2 Department of Movement Sciences, Maastricht University, Maastricht, the Netherlands 3 Department of Endocrinology, University Hospital Groningen, Groningen, the Netherlands Correspondence to: Dr ...